Prosensa to Present at the 66th Annual American Academy of Neurology (AAN) Annual Meeting and the 39th Annual Deutsche Bank

Prosensa to Present at the 66th Annual American Academy of Neurology (AAN)
Annual Meeting and the 39th Annual Deutsche Bank Health Care Conference

Leiden, The Netherlands, April 28, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding
N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare
diseases with a high unmet medical need, today announced that it will present
at the following US conferences:

▪66^th American Academy of Neurology (AAN) Annual Meeting,Philadelphia, PA

Poster presentation:Emerging Science Session: 6:15pm EDT on Wednesday, April
30, 2014

Drisapersen treatment for Duchenne muscular dystrophy: results of a 96-week
follow-up of an open-label extension study following two placebo-controlled
trials

Presenter: Dr. Nathalie Goemans

The poster includes results up to Week 48 from the second open-label extension
study of drisapersen treatment in boys with DMD (DEMAND IV/DMD114349), who had
previously completed a 48-week, double-blind, placebo-controlled treatment
phase in one of two Phase II feeder studies (DEMAND II/DMD114117 and DEMAND
III/DMD114044).

Breakfast Briefing (by invitation only): 7:30 -9:00am EDT on Thursday, May 1,
2014

Corporate Update: Hans Schikan, CEO & Giles Campion, CMO

Poster Presentation: Dr. Nathalie Goemans

Q&A: Prosensa Management, Dr. Nathalie Goemans (live) and Dr. Craig McDonald
(by phone)

Dr. Goemans is a pediatrician, child neurologist and Head of the Neuromuscular
Reference Center for Children at the University Hospitals Leuven (UHL). She is
actively involved in the development of protocols for international
multicentre trials and is an investigator in clinical trials in Duchenne
Muscular Dystrophy (DMD).

Dr. McDonald is a Professor and Chair of Physical Medicine and Rehabilitation
and a Professor of Pediatrics at the University of California Davis School of
Medicine. He is an internationally recognized expert in the clinical
management and rehabilitation of neuromuscular diseases including muscular
dystrophies and the development of novel outcome measures for clinical
trials.

▪39^th Annual Deutsche Bank Health Care Conference, Boston, MA

Fireside Chat: 2:10pm EDT on Wednesday, May 7, 2014; Berndt Modig, CFO

Live webcasts of Prosensa's presentations at the AAN Breakfast Briefing and
the Deutsche Bank Health Care Conference will be accessible through the
Investors & Media section of the corporate website at
http://ir.prosensa.eu/events.cfm and will be archived for 90 days.

Notes to editors

About Prosensa Holding N.V.

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the
discovery and development of RNA-modulating therapeutics for the treatment of
genetic disorders. Its primary focus is on rare neuromuscular and
neurodegenerative disorders with a large unmet medical need, including
Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's
disease.

Prosensa's current portfolio includes six compounds for the treatment of DMD,
all of which have received orphan drug status in the United States and the
European Union. The compounds use an innovative technique called exon-skipping
to provide a personalized medicine approach to treat different populations of
DMD patients. www.prosensa.com

CONTACT: Prosensa Holding N.V.
         Celia Economides, Senior Director IR & Corporate Communications
         Phone: +1 917 941 9059
         Email: c.economides@prosensa.nl

Prosensa Holding B.V. Logo
 
Press spacebar to pause and continue. Press esc to stop.